Last reviewed · How we verify
NCT07513922
The Correlation Between hs CRP TG Triglycerides Glucose Index in NAFLD and Liver Fibrosis
trial testing • Fasting triglycerides (TG) • Fasting plasma glucose • High-sensitivity C-reactive protein (hs-CRP) • Liver enzymes (ALT, AST, GGT) • Platelet count • HbA1c • Lipid profile (total cholesterol, HDL-C, in Liver Fibrosis in 96 participants. Not yet recruiting.
2 October 2027
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 96 |
| Start date | 2 October 2026 |
| Primary completion | 2 October 2027 |
| Estimated completion | 2 December 2027 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- • Fasting triglycerides (TG) • Fasting plasma glucose • High-sensitivity C-reactive protein (hs-CRP) • Liver enzymes (ALT, AST, GGT) • Platelet count • HbA1c • Lipid profile (total cholesterol, HDL-C,
Conditions studied
- Liver Fibrosis — all drugs for Liver Fibrosis →
Sponsor
Assiut University
Who can join
Adults 18 to 85, any sex, with Liver Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Correlation between hs CRP TG triglycerides Glucose index in NAFLD and liver fibrosis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07513922
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Fibrosis
Currently open trials in the same condition.
- NCT07031089 — City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the · recruiting
- NCT06940375 — Incidence of Liver Disease-Related Outcomes in People With HIV · recruiting
- NCT07271576 — Research on the Protective Effects of Phycocyanin Against Liver Fibrosis and Cirrhosis · NA · recruiting
- NCT07069725 — The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Partic · Phase 1 · recruiting
- NCT07122700 — Evaluation of Non-Invasive Tests for Metabolic Liver Disease · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07513922 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07513922.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing